

A Translational Approach to Cardioprotection

ABOUT THE LECTURE

Heart failure is one of the leading causes of death and disability in Singapore and worldwide. As such, new treatments are needed to reduce the onset and progression of cardiac dysfunction, in order to prevent the onset of heart failure, and improve health outcomes. In acute myocardial infarction (AMI) patients, this may be achieved through the discovery of novel treatments for reducing myocardial infarct size, preventing post-infarct adverse cardiac remodelling, and preserving systolic function. Heart failure may also be prevented by improving the delivery of post-AMI patient care in terms of optimizing secondary prevention therapies using telemedicine strategies. In patients with hypertrophic cardiomyopathy, a condition characterized by impaired diastolic function, HF may be prevented by using human iPSC-derived cardiomyocytes to identify novel treatment targets for improving cardiomyocyte relaxation. In this talk, I review the therapeutic potential of these different treatment strategies to prevent heart failure and improve health outcomes in both AMI patients and patients with cardiomyopathy.

Speaker: **Prof Derek Hausenloy**
Cardiovascular & Metabolic Disorders Programme
Duke-NUS Medical School
Senior Consultant
National Heart Centre Singapore (NHCS)

Host: **Prof Jonathan Crowston**
Neuroscience and Behavioural Disorders Programme
Duke-NUS Medical School

Date: **Friday, 25 September 2020**

Time: **2.00 PM - 3.00 PM**

Contact Person: **Ms Kathleen Chan (kathleen.chan@duke-nus.edu.sg)**
Duke-NUS Research Affairs Department



ABOUT THE SPEAKER

Derek Hausenloy is a clinician scientist whose main research focus is discovering novel therapies for protecting the heart against AMI and heart failure, using cellular and animal models of acute ischemia/reperfusion injury, cardiac imaging, proof-of-concept clinical studies, and large multi-centre outcome studies. He also uses human iPSC-derived cardiomyocytes to model cardiac diseases including cardiomyopathies to elucidate the underlying mechanisms, and discover novel treatment targets.

Please click [here](#) for registration